Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 Combined With Chemotherapy for Induction Therapy in Adults With Newly Diagnosed T-ALL
NCT07585734Phase 2Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cm313 in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Apr 2025; status: withdrawn.
02
Drugs
cm313
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07585734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585734.